The knowledge map
The ten clinical domains of nephro-obesity.
The care of the patient with obesity and kidney disease sits between two fields — trained deeply in neither general nephrology nor endocrinology. This map lays out the ground it covers, organised around the cardiovascular-kidney-metabolic (CKM) continuum.
Why a separate map
Nephrology fellowships train glomerular disease, dialysis, and transplant in depth, but treat obesity mostly as a comorbidity. Endocrinology and obesity-medicine training own incretin pharmacology and metabolic disease, but rarely the failing nephron — dose de-indexing, renal-safety surveillance, the protein dilemma, ORG histology. The clinically important material lives precisely in the overlap.
Anchored to the AHA cardiovascular-kidney-metabolic (CKM) framework (2023 advisory; first multisociety AHA/ACC/ADA/ASN guideline, 2026), the KDIGO Obesity–CKD Controversies Conference (Prague 2024), and the ASN Kidney Health Guidance on obesity (JASN 2024).
Read the case for the discipline →The foundation beneath every domain
Two problems run through all ten domains and are barely addressed in fellowship. GFR measurement: eGFR is unreliable in obesity — creatinine generation tracks muscle mass, BSA-indexing (1.73 m²) must be de-indexed for dosing, cystatin C is itself affected by adiposity, and hyperfiltration masks early nephron loss. Pharmacology: volume of distribution (hydrophilic vs lipophilic) alters nearly every dose.
Jump to a domain
1 · Obesity–kidney axis2 · Diagnosis & risk stratification
3 · Pharmacotherapy & renal safety4 · Nutrition & the protein dilemma
5 · Metabolic & bariatric surgery6 · Transplantation
7 · The dialysis population8 · Special populations
9 · Stone & bone metabolism10 · Integrated care & scholarship
Domain 01 · Mechanism
Pathophysiology of the obesity–kidney axis
Under-trained: the mechanistic model that links a patient phenotype to a drug target — beyond „obesity is a risk factor.“
- Obesity-related glomerulopathy: glomerulomegaly, adaptive hyperfiltration, secondary FSGS. Clinically atypical — usually subnephrotic proteinuria despite heavy protein excretion, rarely hypoalbuminaemia or oedema, so it is under-recognised.
- The therapeutic hinge: weight reduction (bariatric or GLP-1/GIP) can drive proteinuria into remission. The general nephrologist has neither the pharmacotherapy nor the indication logic; the obesity physician does not read the biopsy. That overlap is the uplift.
- Renal hemodynamics: single-nephron GFR, glomerular hypertension, RAAS and sympathetic activation.
- Adipokines (leptin, adiponectin, resistin), lipotoxicity, ectopic renal-sinus fat, tubular sodium retention.
- Uric-acid/fructose metabolism, the gut microbiome–bile-acid axis (FXR/TGR5), cellular senescence — evolving targets.
- Weight-loss–dependent vs proposed weight-loss–independent renoprotection of incretins (hemodynamic, natriuretic, anti-inflammatory) — the magnitude of the weight-independent component is still debated.
- Gene–environment risk (APOL1, monogenic obesity); the MASLD/MASH–CKD liver–kidney continuum.
Domain 02 · Diagnosis
Diagnosis and risk stratification
Under-trained: seeing past BMI and creatinine — the two most misleading numbers in this population.
- Critiquing BMI; body-composition assessment (DXA, bioimpedance), visceral adiposity, sarcopenic obesity.
- Cystatin-C vs creatinine eGFR in obesity, including the CKD-EPI 2021 combined creatinine–cystatin C equation; BSA-indexing vs de-indexing for drug dosing; when to order measured GFR.
- Interpreting albuminuria in the setting of hyperfiltration — a „normal“ eGFR can mask early nephron loss.
- Histologic criteria of ORG (secondary FSGS with glomerulomegaly, perihilar sclerosis, milder podocyte foot-process effacement than primary FSGS) vs diabetic nephropathy and hypertensive nephrosclerosis, into which ORG is routinely misclassified.
- The kidney biopsy is technically harder in obesity: greater skin-to-capsule distance, poorer ultrasound penetration, standard needles that may not reach the kidney, and higher rates of non-diagnostic cores and bleeding.
- Appraising emerging diagnostics: metabolomic/urinary-EV biomarkers, quantitative MRI fat, AI prediction — validated vs research-stage.
Domain 03 · Pharmacology
Pharmacotherapy and renal safety Core
The strongest point of differentiation — and the highest-turnover domain. This is the material that falls squarely between the general nephrologist and the obesity-medicine physician.
- Renal evidence is agent- and endpoint-specific: semaglutide in FLOW (kidney-outcome trial); tirzepatide kidney data are exploratory/post-hoc (SURPASS-4, HR 0.58 [0.43–0.80]) — broader GLP-1 / dual-agonist renal evidence varies by agent and endpoint.
- Triple agonists (retatrutide): phase-2 post-hoc UACR/eGFR signals, the phase-2b renal-function study TRANSCEND-CKD (NCT05936151; iohexol mGFR, topline expected 2026), and the pivotal phase-3 outcomes trial TRIUMPH-Outcomes (NCT06383390; not before 2028–2029) — investigational; no reported phase-3 kidney-outcome results yet.
- Amylin analogs and combinations (cagrilintide, CagriSema); oral small molecules — renal PK, volume of distribution, electrolyte/acid–base effects.
- SGLT2 inhibitors cardiorenal effects; non-steroidal MRAs (finerenone; FIDELIO-DKD / FIGARO-DKD).
- The emerging multi-pillar model — RAAS blockade + SGLT2i + non-steroidal MRA + incretin — and rational sequencing in HFpEF, MASH, polypharmacy (not yet a guideline-codified protocol).
- Renal-safety surveillance: GI losses with GLP-1/GIP → hypokalaemia, metabolic alkalosis, and prerenal AKI; topiramate metabolic acidosis; oxalate nephropathy after malabsorptive surgery.
- Bariatric metabolic sequelae: refeeding, thiamine deficiency, hypokalaemia/-magnesaemia/-calcaemia, secondary hyperparathyroidism, vitamin-D deficiency.
- Deprescribing and the pharmacology of weight regain after discontinuation.
Domain 04 · Nutrition
Nutrition & the protein dilemma
Under-trained: how to strip fat while preserving muscle and managing protein/electrolyte load as GFR falls.
- Reconciling weight-loss and muscle-preservation goals with protein restriction in advanced CKD.
- Safety of very-low-calorie diets in CKD; generally avoid unsupervised ketogenic diets in advanced CKD; micronutrient load during active loss.
- Preventing sarcopenia; behavioral medicine — motivational interviewing, eating-disorder screening, weight stigma.
- Weight regain, maintenance, and nutrition after anti-obesity-drug discontinuation.
Domain 05 · Surgery
Metabolic & bariatric surgery
Under-trained: co-managing the surgical patient with CKD — often the most effective intervention and a bridge to transplant.
- Effects on albuminuria, eGFR trajectory, and CKD progression; surgery vs pharmacotherapy for renoprotection and transplant access.
- Candidate selection in CKD/ESKD; surgery as a bridge to listing.
- Endoscopic options (endoscopic sleeve gastroplasty) for high-risk patients unfit for surgery.
- Postoperative renal complications: oxalate nephropathy (particularly after malabsorptive procedures such as Roux-en-Y), nephrolithiasis, AKI; long-term stone/bone surveillance.
Domain 06 · Transplant
Transplantation
Under-trained: managing weight across the transplant continuum — a listing barrier before, a metabolic driver after.
- Pre-listing: BMI cut-offs (many centres 35–40) restrict transplant access for people with obesity — an equity issue as much as a clinical one.
- Bridge to transplant: bariatric surgery (especially sleeve) — timing, altered immunosuppressant absorption after surgery, nutritional sequelae; GLP-1 RAs increasingly used for pre-listing weight reduction.
- Post-transplant: weight gain in the first year is the rule; PTDM/NODAT with obesity as the main risk factor, potentiated by tacrolimus and steroids.
- Recurrent or de-novo ORG in the graft; GLP-1 RAs in recipients — interactions with immunosuppression and safety are barely charted territory.
- Immunosuppressant dosing in obesity (weight-based vs fixed, CNI pharmacokinetics); higher surgical complication rates.
- Living donation: the obese donor faces additive hyperfiltration — remnant-kidney plus obesity-driven — a specific risk to weigh.
Domain 07 · Dialysis
The dialysis population
Under-trained and clinically contested: weight management under renal replacement therapy is genuinely under-studied — and the modality itself interacts with adiposity.
- Hemodialysis access: AVF creation is harder with deep vessels — higher primary failure, more need for superficialisation/transposition, and difficult cannulation.
- Adequacy and the „V problem“: urea distribution volume vs body weight, and BSA- vs V-normalisation of Kt/V — which weight to target for dose and drug dosing.
- The obesity survival paradox (higher BMI, better HD survival): must be understood — and muscle vs fat mass distinguished — to avoid mismanagement, not used as a blanket argument against treating obesity on RRT.
- Peritoneal dialysis — the sharpest nephro-obesity intersection: the glucose-based dialysate delivers a substantial calorie load, driving weight gain, hyperglycaemia, dyslipidaemia. Steer with icodextrin, prescription changes, and metabolic monitoring.
- PD catheter in a thick abdominal wall/omentum: higher leak, hernia, and exit-site risk; adequacy at large body volume.
- Intentional weight loss may be appropriate when needed for transplant access, mobility, metabolic complications, or PD mechanics; individualise for the HD or PD patient.
Domain 08 · Special populations
Special populations
Under-trained: the field runs across the lifespan and into monogenic, reproductive, and oncologic contexts.
- Pediatric obesity with CKD and transition to adult care.
- Monogenic/syndromic obesity with renal involvement (Bardet–Biedl, Alström); APOL1-related risk.
- Obesity, CKD, and preeclampsia in pregnancy; pre-conception considerations for incretins as safety data emerge.
- Geriatric sarcopenic obesity and frailty.
- The onco-nephrology interface: obesity is a shared risk factor for several cancers, and weight management, drug dosing, and AKI risk intersect in the CKD patient with cancer.
Domain 09 · Stone & bone
Stone and bone metabolism
Under-trained: metabolic and post-surgical stone risk and CKD-MBD take distinctive forms in obesity.
- Obesity raises stone risk independently — especially uric-acid stones (low urine pH in insulin resistance), also calcium oxalate — tightly coupled to metabolic syndrome.
- The bariatric paradox: Roux-en-Y drives enteric hyperoxaluria → oxalate stones and oxalate nephropathy/CKD — the obesity therapy can injure the kidney. Sleeve carries much less risk.
- Interpreting the 24-hour urine in metabolic context; how stone risk shifts during weight loss; CKD-MBD features specific to obesity and bone-health plans post-bariatric.
Domain 10 · Integration
Integrated care, delivery & scholarship
Under-trained: building the multidisciplinary CKM clinic and studying the discipline, not just practising it.
- Designing a multidisciplinary cardio-reno-metabolic clinic around the CKM staging framework.
- Implementation science and health equity — access and cost of anti-obesity agents, disparities in underserved populations.
- Digital health (telemedicine, wearables, AI-assisted decision support — not yet validated for routine nephro-obesity care); pharmacovigilance (FAERS), registry and QI methods.
- Integrating guidance across the CKM guideline, KDIGO, and obesity-medicine boards.
Each domain connects to the evidence.
Studies in the library are tagged to these domains — from FLOW and finerenone to the maturing triple-agonist trials.
Go to the study library →⚠︎Educational only. This map is a professional-education overview, not individual medical advice. Nephrobesity is an emerging clinical focus, not an accredited board subspecialty. Verify current data before applying to care.